Atalanta Therapeutics
PrivateLast Round
Series B
Jan 28, 2025
Total Funding Raised
$207M
Company Overview
Atalanta Therapeutics is a biotechnology company that develops RNA interference therapeutics aimed at treating neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Atalanta Therapeutics Comparables
Compare Atalanta Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| City Therapeutics | 84% | |
| Switch Therapeutics | 83% | |
| Trace Neuroscience | 83% |
Atalanta Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 28, 2025 | ||||
| Series A | Jan 11, 2021 |
Key People
Founding team and executive leadership
Atalanta Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EQT Life Sciences | Series B |
| EQT Ventures | Series B |
| Mirae Asset | Series B |
| abrdn Inc. | Series B |
| F-Prime Capital | Series B, Series A |
| Genentech | Series A |
| GHR Foundation | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2025
Alicia Secor stepped down as Chief Executive Officer.
- Jun 18, 2025
Joanne Kotz appointed as new Chief Executive Officer.
Atalanta Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Atalanta Therapeutics's valuation, stock price, and market status.
Is Atalanta Therapeutics a public or private company?
Atalanta Therapeutics is a private company.
What is the current stock price of Atalanta Therapeutics?
Atalanta Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Atalanta Therapeutics worth (valuation)?
Valuation information for Atalanta Therapeutics is not publicly available.
Can I buy Atalanta Therapeutics stock?
Atalanta Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Atalanta Therapeutics's last funding round?
Atalanta Therapeutics's most recent funding round was Series B on January 28, 2025.
Who are the main investors in Atalanta Therapeutics?
Key investors in Atalanta Therapeutics include EQT Life Sciences, EQT Ventures, F-Prime Capital, Sanofi Ventures.
Will Atalanta Therapeutics IPO soon?
No public IPO plans have been announced for Atalanta Therapeutics.
How can I track Atalanta Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Atalanta Therapeutics's secondary market activity and sign up for updates.